Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX : revenue, balance sheet and financial ratios

INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX is a French company founded 8 years ago, specialized in the sector Analyses, essais et inspections techniques. Based in CHAMBLY (60230), this company of category PME shows in 2023 a revenue of 619 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Historique financier - INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX (SIREN 831563226)
Indicador 2023 2022 2021 2020 2019 2018
Ingresos 618 664 € N/C N/C N/C N/C N/C
Resultado neto 105 507 € 0 € 0 € 0 € 0 € 0 €
EBITDA 116 805 € N/C N/C N/C N/C N/C
Margen neto 17.1% N/C N/C N/C N/C N/C

Ingresos y cuenta de resultados

In 2023, INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX achieves revenue of 619 k€. After deducting consumption (26 k€), gross margin stands at 592 k€, i.e. a rate of 96%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 117 k€, representing 18.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 106 k€, i.e. 17.1% of revenue. This profit can be retained or distributed to shareholders.

Ingresos (2023) ?
Ingresos
Definición
Importe total de las ventas de bienes y servicios realizadas por la empresa.
Fórmula
Ventas de mercancías + Producción vendida

618 664 €

Margen bruto (2023) ?
Margen bruto
Definición
Diferencia entre los ingresos y el coste de las mercancías vendidas.
Fórmula
Ingresos - Compras consumidas

592 298 €

EBITDA (2023) ?
EBITDA (Excedente bruto de explotación)
Definición
Ressource générée par l'activité courante, avant amortissements et charges financières.
Fórmula
Valor añadido - Gastos de personal - Impuestos
Interpretación
Positivo = actividad rentable

116 805 €

EBIT (2023) ?
EBIT (Resultado de explotación)
Definición
Resultado operativo, incluyendo amortizaciones y provisiones.
Fórmula
EBITDA - Amortizaciones y provisiones + Reversiones

105 525 €

Resultado neto (2023) ?
Resultado neto
Definición
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Fórmula
Resultado corriente + Resultado excepcional - Impuesto sobre beneficios

105 507 €

Margen EBITDA (2023) ?
Margen EBITDA
Definición
Mide la rentabilidad operativa de la empresa.
Fórmula
(EBE / CA) x 100
Interpretación
> 10% : Buena rentabilidad
5-10% : Media
< 5% : Faible

18.9%

Chargement du compte de résultat...

Évolution graphique

Mostrar :

Activo

Chargement des données...

Pasivo

Chargement des données...

Ratios de solvencia y endeudamiento

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 0%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 18.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Ratio de endeudamiento (2023) ?
Ratio de endeudamiento
Definición
Mide la proporción de deuda respecto a los fondos propios.
Fórmula
(Deuda financiera / Fondos propios) x 100
Interpretación
< 50% : Faible
50-100% : Moderado
> 100% : Alto

0.037%

Autonomía financiera (2023) ?
Autonomía financiera
Definición
Porcentaje de fondos propios en la financiación total.
Fórmula
(Fondos propios / Total balance) x 100
Interpretación
> 30% : Buena autonomía
20-30% : Media
< 20% : Faible

0.014%

Flujo de caja / Ingresos (2023) ?
Flujo de caja / Ingresos
Definición
Capacité d'autofinancement rapportée au chiffre d'affaires.
Fórmula
(CAF / CA) x 100
Interpretación
Cuanto mayor sea el ratio, más liquidez genera la empresa

18.858%

Capacidad de reembolso (2023) ?
Capacidad de reembolso
Definición
Número de años necesarios para reembolsar las deudas con el flujo de caja.
Fórmula
Dettes financières / CAF
Interpretación
< 3 años : Excelente
3-5 años : Correcto
> 5 años : Attention

0.001

Ratio de obsolescencia (2023) ?
Ratio de obsolescencia
Definición
Mide el grado de desgaste del inmovilizado material.
Fórmula
Amortización acumulada / Inmovilizado bruto x 100
Interpretación
< 50% : Activos recientes
50-70% : Desgaste normal
> 70% : Activos envejecidos

71.9%

Evolución de indicadores de solvencia
INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX

Positionnement sectoriel

Debt ratio
0.04 2023
2021
2022
2023
Q1: 0.0
Méd: 11.27
Q3: 55.27
Good

In 2023, the debt ratio of INTERNATIONAL MEDICAL INS... (0.04) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
0.01% 2023
2021
2022
2023
Q1: 11.39%
Méd: 36.33%
Q3: 58.53%
Average

In 2023, the financial autonomy of INTERNATIONAL MEDICAL INS... (0.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.0 years 2023
2023
Q1: 0.0 years
Méd: 0.01 years
Q3: 1.1 years
Good

In 2023, the repayment capacity of INTERNATIONAL MEDICAL INS... (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Ratios de liquidez

The liquidity ratio (= Current assets / Current liabilities) stands at 115.82. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.0x. Danger: operating income does not cover interest charges, unsustainable situation.

Ratio de liquidez (2023) ?
Ratio de liquidez
Definición
Capacidad para pagar las deudas a corto plazo con el activo circulante.
Fórmula
Activo circulante / Pasivo circulante
Interpretación
> 1.5 : Muy bueno
1-1.5 : Correcto
< 1 : Risque de liquidité

115.82

Cobertura de intereses (2023) ?
Cobertura de intereses
Definición
Capacidad para cubrir los gastos financieros con el resultado de explotación.
Fórmula
EBIT / Gastos financieros
Interpretación
> 3 : Confortable
1.5-3 : Acceptable
< 1.5 : Riesgo

0.015

Evolución de indicadores de liquidez
INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX

Positionnement sectoriel

Liquidity ratio
115.82 2023
2021
2022
2023
Q1: 130.04
Méd: 208.63
Q3: 353.23
Watch

In 2023, the liquidity ratio of INTERNATIONAL MEDICAL INS... (115.82) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
0.01x 2023
2023
Q1: 0.0x
Méd: 0.03x
Q3: 2.09x
Average

In 2023, the interest coverage of INTERNATIONAL MEDICAL INS... (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Necesidad de fondo de rotación (NFR) y plazos de pago

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 127 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 218 days. Excellent situation: suppliers finance 91 days of the operating cycle (retail model). WCR is negative (-11 days): operations structurally generate cash.

NFR de explotación (2023) ?
NFR de explotación
Definición
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
Fórmula
Stocks + Créances clients - Dettes fournisseurs
Interpretación
Negativo = tesorería liberada
Positivo = necesidad de financiación

-18 300 €

Crédito clientes (2023) ?
Crédito clientes (días)
Definición
Plazo medio de cobro a clientes.
Fórmula
(Cuentas por cobrar / Ingresos con IVA) x 360
Interpretación
< 45j : Bueno
45-60j : Medio
> 60j : Largo

127 j

Crédito proveedores (2023) ?
Crédito proveedores (días)
Definición
Plazo medio de pago a proveedores.
Fórmula
(Cuentas por pagar / Compras con IVA) x 360
Interpretación
Cuanto más largo sea el plazo, mejor para la tesorería

218 j

Rotación de inventario (2023) ?
Rotación de inventario (días)
Definición
Duración media de almacenamiento de mercancías o materiales.
Fórmula
(Existencias / Coste de compra) x 360
Interpretación
Cuanto menor sea el ratio, más rápida es la rotación

0 j

NFR en días de ingresos (2023) ?
NFR en días de ingresos
Definición
Expresa el fondo de maniobra operativo en días de facturación.
Fórmula
(BFR exploitation / CA) x 360
Interpretación
Cuantos menos días, mejor gestión del capital circulante

-11 j

Evolución del NFR y plazos
INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX

Positionnement de INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX dans son secteur

Comparación con el sector Analyses, essais et inspections techniques

Estimación de valoración

Indicative estimate only : the number of comparable transactions in this sector is limited (38 transactions). This range of 89 073€ to 401 656€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2023
Indicative
89k€ 190k€ 401k€
190 688 € Range: 89 073€ - 401 656€
NAF 5 année 2023
How is this estimate calculated?

This estimate is based on the analysis of 38 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Analyses, essais et inspections techniques)

Compare INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX with other companies in the same sector:

Voir toutes les statistiques du secteur Analyses, essais et inspections techniques

Frequently asked questions about INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX

What is the revenue of INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX ?

The revenue of INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX in 2023 is 619 k€.

Is INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX profitable?

Yes, INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX generated a net profit of 106 k€ in 2023.

Where is the headquarters of INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX ?

The headquarters of INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX is located in CHAMBLY (60230), in the department Oise.

Where to find the tax return of INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX ?

The tax return of INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX operate?

INTERNATIONAL MEDICAL INSTITUTE OF TOXICOLOGY AND PHARMACOLOGY I-MITOX operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.